摘要
目的探讨奥氮平治疗急性期精神病的临床效果和安全性。方法选择本院2010年1月～2013年1月收治的87例急性期精神病患者为研究对象，给予奥氮平治疗，观察其治疗前后简明精神病评定量表（BPRS）评分、治疗后的总有效率以及不良反应。结果87例患者治疗后BPRS评分明显低于治疗前，差异有统计学意义（P（0．05）。治疗后治愈58例（66．67％），显效18例（20．69％），有效5例（5．74％），无效6例（6．90％），总有效率为93．10％。87例患者治疗后未出现严重心、肝、肾等功能损害，仅出现轻度嗜睡3例、乏力2例、便秘2例、头昏1例、体重增加1例，无需进行特殊处理，不良反应发生率为10．34％。结论奥氮平治疗急性期精神病临床效果显著，且安全可靠，值得临床广泛推广。
Objective To investigate the clinical efficacy and safety of olanzapine in the treatment of the patients with acute psychosis.Methods 87 cases of patients with acute psychosis admitted to our hospital from January 2010 to Jan- uary 2013 were selected,all were given olanzapine,brief psychiatric rating scale （BPRS） before and after treatment, clin- ical efficacy and safety was observed.Results After treatment, the BPRS score was lower than that before treatment,the difference was significant （P〈0.05）.The total effective rate of 87 cases was 93.10%,of whom 58 cases （66.67%） were cured, 18 cases （20.69%） were markedly,5 cases （5.74%） were effective,6 cases （6.90%） were invalid.Severe heart,liver, kidney and other damage did not appear,there were only mild drowsiness 3 cases,fatigue 2 cases,constipation 2 cases,dizziness 1 case,weight I case,without the need for special treatment,the adverse reaction rate was lO.34%.Conclusion Olanzap- ine has a significant effect on treating acute psychosis,which is safe and worthy of clinical widely spreading.
出处
《中国当代医药》
2014年第2期59-60,共2页
China Modern Medicine
关键词
急性期精神病
奥氮平
临床疗效
不良反应
Acute psychosis
Olanzapine
Clinical efficacy
Adverse reaction
